{"product_id":"genmab-five-forces-analysis","title":"Genmab Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGenmab faces intense competitive rivalry driven by a concentrated biotech landscape, high supplier bargaining from specialized CMC partners, and moderate buyer power from large payers; IP strength and pipeline differentiation lower substitute and new entrant threats.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Genmab’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab depends on specialized CROs for complex bispecific and hexameric antibody trials; only a small fraction—estimated \u0026lt;10% of global CROs—have this expertise, giving suppliers moderate leverage.\u003c\/p\u003e\n\u003cp\u003eSwitching mid-Phase 3 is costly: average delay costs ~€5–15M per month and can add 6–12 months, so Genmab faces strong lock-in and higher bargaining power for those niche CROs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSole-Source Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab depends on patent-protected reagents and cell lines from a few specialist suppliers; in 2025 about 60–70% of critical biologics inputs for antibody firms come from sole-source vendors, raising price and supply risk.\u003c\/p\u003e\n\u003cp\u003eReplacing a supplier can take 12–24 months of regulatory validation, so a single-site outage or a 20–30% price hike could materially raise COGS and delay launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized CMO Capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContract Manufacturing Organizations (CMOs) with large-scale GMP biologics capacity hold outsized leverage as Genmab scales: global high‑end bioreactor utilization hit ~92% in 2024 and top-tier CDMOs charge premium slot fees—examples include €50–€150M+ multi-year supply contracts reported in 2023–25—so securing long-term capacity for complex antibodies is costly and raises supplier bargaining power materially.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Licensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab relies on third-party IP to complement its DuoBody and HexaBody platforms; 2024 filings show licensing and royalty expenses around DKK 400–600m annually, a fixed R\u0026amp;D cost that compresses margin. Suppliers keep leverage because their patents are often essential for bispecific and multispecific antibody development, raising switching costs and timeline risk. In 2025, a single critical license delay can add 6–12 months to clinical timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDKK 400–600m yearly licensing\/royalties\u003c\/li\u003e\n\u003cli\u003eEssential patents → high supplier leverage\u003c\/li\u003e\n\u003cli\u003eSwitching adds 6–12 months\u003c\/li\u003e\n\u003cli\u003eFixed cost pressure on margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe specialized labor market for antibody-engineering researchers is fiercely competitive in late 2025; industry surveys show biotech and pharma hiring demand up ~18% YoY and median biotech senior scientist pay rose to ~$175k–$220k in 2024–25.\u003c\/p\u003e\n\u003cp\u003eGenmab competes with Big Pharma and well-funded startups, so this human capital behaves like a supplier with leverage over compensation, equity, and lab resource allocation.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eHiring demand +18% YoY (2025)\u003c\/li\u003e\n\u003cli\u003eSenior scientist median pay $175k–$220k (2024–25)\u003c\/li\u003e\n\u003cli\u003eHigh leverage on compensation and lab resources\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power strains Genmab: high bioreactor use, single‑source inputs, rising COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate–high leverage over Genmab due to scarce niche CRO\/CMO capacity (global high‑end bioreactor utilization ~92% in 2024), sole‑source reagents\/patents (60–70% critical inputs single‑sourced in 2025), long switching\/validation (12–24 months) and recurring licensing costs (DKK 400–600m\/year), raising COGS and timeline risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioreactor utilization (2024)\u003c\/td\u003e\n\u003ctd\u003e~92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle‑source critical inputs (2025)\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching time\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense\/royalty cost\u003c\/td\u003e\n\u003ctd\u003eDKK 400–600m\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Genmab, this Porter's Five Forces overview uncovers competitive dynamics, supplier\/buyer power, threat of substitutes and new entrants, and identifies disruptive forces and market barriers that shape its pricing power and long-term profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Genmab—enabling rapid assessment of competitive pressures and therapeutic pipeline risks to inform licensing, R\u0026amp;D prioritization, and portfolio strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Programs and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpnational health systems and medicare push hard on oncology drug costs with us spending controls european technology assessment negotiations driving average price discounts of versus list in major markets\u003e\u003cpas a maker of high-cost oncology biologics genmab gmab faces sensitivity to us state and federal price transparency laws enacted in that increase rebate visibility narrow net pricing.\u003e\u003cpthese institutional payers can exclude therapies from formularies or demand outcome-based contracts a iqvia report showed payer-driven access restrictions affected launch uptake by up to for new cancer therapies.\u003e\n\u003c\/pthese\u003e\u003c\/pas\u003e\u003c\/pnational\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs in the US act as powerful intermediaries that set formulary placement; the top three PBMs—CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth)—cover roughly 75% of commercially insured lives as of 2025, so their formulary decisions sway drug uptake. They leverage ~200+ million covered lives to demand rebates often 20–50% for high-cost oncology and specialty drugs, pressuring Genmab on net pricing. Failing to secure preferred placement with a major PBM can block access to a large portion of Genmab’s addressable US market, materially cutting peak sales projections. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Hospital Purchasing Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge hospital networks and Group Purchasing Organizations (GPOs) consolidate demand to secure steep discounts on biologics; in 2024 US GPOs accounted for over 70% of hospital purchasing, pressuring list prices for Genmab’s IV and in-clinic antibodies.\u003c\/p\u003e \n\u003cp\u003eBecause Genmab’s products are mostly given in hospitals, GPO-driven formularies and protocols can sway brand choice and volume, forcing rebate-heavy contracts; bulk purchasing leverage often demands price concessions of 20–40% on list prices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab co-develops with Janssen, AbbVie, Pfizer, etc., who fund late-stage trials and handle commercialization, making them de facto internal customers with strong leverage over program terms.\u003c\/p\u003e\n\u003cp\u003eThese partners control global distribution and sales—e.g., Janssen-paid royalties on DARZALEX (daratumumab) drove Genmab revenue of DKK 10.4bn in 2024—so contract renewals face high bargaining pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development with Big Pharma\u003c\/li\u003e\n\u003cli\u003ePartners set profit-sharing and strategic direction\u003c\/li\u003e\n\u003cli\u003eGlobal distribution control = high renewal leverage\u003c\/li\u003e\n\u003cli\u003e2024 Genmab revenue DKK 10.4bn shows partner-driven cash flows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Regulatory Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganized patient groups lobby payers and regulators, pushing for inclusion of Genmab therapies in public formularies; in 2024, patient advocacy campaigns helped secure reimbursement for two oncology drugs across EU markets, affecting expected uptake and pricing.\u003c\/p\u003e\n\u003cp\u003eThough not direct buyers, these groups sway HTA (health technology assessment) outcomes and reimbursement, creating indirect customer power that can lower realized prices and extend timelines.\u003c\/p\u003e\n\u003cp\u003eDemand for affordable access leads Genmab to run patient assistance programs; such programs reduced net revenue for biotech peers by 3–7% in 2023, a likely benchmark for Genmab.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy impacts reimbursement decisions and pricing\u003c\/li\u003e\n\u003cli\u003eIndirect power via HTA\/regulator sway\u003c\/li\u003e\n\u003cli\u003ePatient programs can cut net revenue ~3–7%\u003c\/li\u003e\n\u003cli\u003e2024 EU wins show advocacy-driven uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers \u0026amp; PBMs squeeze pricing: 20–50% rebates, 20–40% discounts, \u0026gt;70% hospital GPO reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppayers eu hta pbms exert high price pressure discounts vs list top-3 us cover of commercial lives and drive rebates gpos\u003e70% hospital purchasing; partner royalties (e.g., DKK 10.4bn Genmab 2024) add renewal leverage; patient advocacy influences HTA and reimbursement; patient-assistance programs cut net revenue ~3–7%.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM coverage\u003c\/td\u003e\n\u003ctd\u003e~75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical discounts\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM rebates\u003c\/td\u003e\n\u003ctd\u003e20–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO hospital share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner-driven rev\u003c\/td\u003e\n\u003ctd\u003eDKK 10.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient program hit\u003c\/td\u003e\n\u003ctd\u003e3–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ppayers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGenmab Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Genmab Porter’s Five Forces analysis you'll receive—no placeholders or mockups. The document displayed is the final, fully formatted file ready for immediate download upon purchase. It contains the complete competitive assessment, insights, and implications you can use right away. What you see is precisely what you’ll get after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746963042681,"sku":"genmab-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/genmab-five-forces-analysis.png?v=1772193776","url":"https:\/\/matrixbcg.com\/products\/genmab-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}